Triepitopic Antibody Fusions Inhibit Cetuximab-Resistant BRAF and KRAS Mutant Tumors via EGFR Signal Repression

Triepitopic Antibody Fusions Inhibit Cetuximab-Resistant BRAF and KRAS Mutant Tumors via EGFR Signal Repression

Dysregulation of epidermal growth factor receptor (EGFR) is a hallmark of many epithelial cancers, rendering this receptor an attractive target for cancer therapy. Much effort has been focused on the development of EGFR-directed antibody-based therapeutics, culminating in the clinical approval of th...

Full description

Bibliographic Details
Main Authors: Manzari, Mandana T. (Contributor), Rosalia, Elizabeth K. (Contributor), Chen, Tiffany Fen-yi (Contributor), Wittrup, Karl Dane (Contributor), Spangler, Jamie Berta (Author)
Other Authors: Massachusetts Institute of Technology. Department of Biological Engineering (Contributor), Massachusetts Institute of Technology. Department of Biology (Contributor), Massachusetts Institute of Technology. Department of Chemical Engineering (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor), Spangler, Jamie B. (Contributor)
Format: Article
Language:English
Published: Elsevier, 2014-11-20T15:02:47Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items